Conventional biologics discovery has long been limited to well-behaved targets with known structural properties. Ainnocence’s AI platform removes these boundaries by identifying non-traditional binding interfaces, allosteric mechanisms, and conformational dynamics that are often overlooked in static modeling.
The company’s proprietary sequence-first AI platform can now virtually explore and optimize up to 10¹⁰–10¹² antibody and protein variants, bringing in-silico precision engineering to a scale that mirrors nature’s own evolutionary processes, all within days instead of months or years.
Ainnocence’s AI engine can virtually explore the full diversity of antibodies at this scale, enabling in-silico multi-objective optimization for binding affinity, specificity, stability, developability in silico and immunogenicity.
Ainnocence is opening CarbonAI® Accelerator slots for biopharma, specialty chemicals, and advanced materials teams seeking to compress timelines or rescue stalled programs. Partners gain hands-on access to the platform, optional on-prem deployment, and dedicated AI-chemistry support.
AINN-P1 is Ainnocence’s protein language foundation model, built to understand protein sequence patterns to power next-generation drug discovery. The new model posts state-of-the-art Spearman correlation scores across four core protein-fitness tasks, reinforcing Ainnocence’s sequence-first drug-discovery platform and underscoring its competitiveness against much larger transformer models from Meta and BioMap.
In affinity maturation applications, SentinusAI® delivered an exceptional 85.7% success rate across 42 projects, achieving affinity improvements from dozens to thousands fold with potencies up to double-digit picomolar levels.
